Is Alterity Therapeutics (ASX: ATH) Stabilising After Volatility at a Key Technical Level?
Alterity Therapeutics (ASX: ATH) is advancing its lead neurodegeneration drug, ATH434, toward Phase 3 trials. Following positive clinical data and a 1-for-50 share consolidation, the stock is holding key technical support around 0.450, awaiting a potential upside breakout.
Is Paradigm Biopharmaceuticals (ASX: PAR) Bottoming Out After Its Prolonged Downtrend?
Paradigm Biopharmaceuticals (ASX: PAR) is an Australian late-stage biotech developing injectable PPS, mainly for osteoarthritis. Its shares have fallen more than 95% since 2020 amid trial delays, dilution and losses, with August 2026 Phase 3 interim data now the key catalyst.
Dimerix (ASX: DXB) Slides Toward $0.19 After Volatile Phase III Trial-Driven Swings
Dimerix slipped toward $0.19 after volatile trading driven by its Phase 3 ACTION3 trial. The biotech continues to swing on sentiment as investors react to clinical updates, balancing long-term DMX-200 hopes against no-revenue uncertainty and regulatory timelines.
Is Breakout in Clinuvel Pharmaceuticals (ASX: CUV) Signalling a Sustainable Bullish Reversal?
CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.
Avecho Biotechnology (ASX: AVE): Breakout Above Long-Term Resistance Puts Trend Sustainability in Focus
Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.
Mesoblast (ASX: MSB) Shares Declined Despite Ryoncil Momentum as Investors Lock In Profits
Mesoblast (ASX: MSB) is transitioning into a commercial-stage biotech as Ryoncil® sales accelerate and its late-stage pipeline advances. While the share price has eased after a strong rally, growing revenue, improving cash flow, and multiple clinical catalysts continue to support its long-term outlook.